AI assistant
Sending…
ELI LILLY & Co — Director's Dealing 2022
Feb 12, 2022
29745_dirs_2022-02-11_c7eafcbc-d6f6-4663-b927-d3bc3e67181d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ELI LILLY & Co (LLY)
CIK: 0000059478
Period of Report: 2022-02-09
Reporting Person: White Anne E. (SVP & Pres-Lilly Neuroscience)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-02-09 | Common Stock | A | 11348 | $243.27 | Acquired | 50352 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-02-09 | Restricted Stock Unit | $ | A | 7264 | Acquired | 2023-02-01 | Common Stock (7264.0) | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.
More from ELI LILLY & Co
Regulatory Filings
2026
May 20
Regulatory Filings
2026
May 11
Regulatory Filings
2026
May 8
Regulatory Filings
2026
May 7
Regulatory Filings
2026
May 6
Regulatory Filings
2026
May 6
Major Shareholding Notification
2026
May 1
Interim / Quarterly Report
2026
Apr 30
Regulatory Filings
2026
Apr 30
Regulatory Filings
2026
Apr 29